Clinical trial
Almonertinib With Concurrent Radiotherapy in The Treatment of Unresectable, Stage Ⅲ Non-small-cell Lung Cancer Harboring EGFR Mutations: A PhaseⅡCohort Study
NCT04636593 is registered in ClinicalTrials.gov with First People's Hospital of Hangzhou as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Almonertinib With Concurrent Radiotherapy in The Treatment of Unresectable, Stage Ⅲ Non-small-cell Lung Cancer Harboring EGFR Mutations: A PhaseⅡCohort Study
- Lead sponsor
- First People's Hospital of Hangzhou
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- August 1, 2020
- Completion date
- December 31, 2022
- Enrollment
- 43 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
egfr activating mutation, non small cell lung cancer, stage iii nsclc